Moderne Therapiekonzepte beim metastasierten Melanom

Immuntherapie und zielgerichtete Therapie bilden die wesentlichen Säulen in der Behandlung des fortgeschrittenen, metastasierten Melanoms. Dieser Beitrag fasst den aktuellen Stand der Behandlungsoptionen zusammen.

Publikationsverlauf

Artikel online veröffentlicht:
31. August 2020

• Literatur

• 1 Friedrich S, Kraywinkel K. Epidemiologie des malignen Melanoms in Deutschland. Der Onkologe 2018; 24: 447-452
• 2 Garbe C, Keim U, Eigentler TK. et al. Time trends in incidence and mortality of cutaneous melanoma in Germany. J Eur Acad Dermatol Venerol 2019;
• 3 Merz R. Melanom – Prävention und Versorgung. TumorDiagn u Ther 2018; 39: 97-99
• 4 Amin MB. (ed). AJCC Cancer Staging Manual. 8. Edition. 2018. ISBN: 978-3-319-40617-6
• 5 Bhatia S, Tykodi SS, Thompson JA. et al. Treatment of metastatic melanoma: an overview. Oncology 2009; 23: 488-496
• 6 Hodi FS, O'Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
• 7 Robert C, Long GV, Brady B. et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015; 372: 320-330
• 8 Hodi FS, Kluger H, Sznol M. et al Durable, long-term survival in previously treated patients with advancedmelanoma (MEL) who received nivolumab (NIVO) monotherapy in aphase I trial. Cancer Res 2016; 76 (Suppl. 14) Abstract CT001
• 9 Schachter J, Ribas A, Long GV. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390: 1853-1862
• 10 Robert C, Ribas A, Hamid O. et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol 2016; 34: 9503-9503
• 11 Larkin J, Chiarion-Sileni V, Gonzalez R. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
• 12 Wolchok JD, Chiarion-Sileni V, Gonzalez R. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377: 1345-1356
• 13 Terheyden P, Krackhardt A, Eigentler T. Systemische Therapie des Melanoms. Der Stellenwert von Checkpoint-Inhibitoren und die Hemmung von intrazellulärer Signaltransduktion. Dtsch Ärztebl Int 2019; 116: 497-504
• 14 Johnson DB, Sosman JA. Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncol 2015; 1: 380-386
• 15 Spagnolo F, Ghiorzo P, Queirolo P. et al. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014; 5: 10206-10221
• 16 Long GV, Stroyakovskiy D, Gogas H. et al. Dabrafenib and Trametinib Versus Dabrafenib and Placebo for Val600 BRAF-mutant Melanoma: A Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial. Lancet 2015; 386: 444-451
• 17 Robert C, Karaszewska B, Schachter J. et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2015; 372: 30-39
• 18 Ascierto PA, McArthur G, Dréno B. et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016; 17: 1248-1260
• 19 Dummer R, Ascierto PA, Gogas HJ. et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018; 19: 603-615
• 20 www.awmf.org/leitlinien/detail/ll/032-024OL.html
• 21 Ribas A, Medina T, Kummar S. et al. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov 2018;
• 22 Papadopoulos KP, Autio KA, Golan T. et al. Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors. J Clin Oncol 2019; 37 (Suppl. 15) 9509-9509
• 23 Ekladious I, Colson YL, Grinstaff MW. Polymer-drug conjugate therapeutics: advances, insights and prospects. Nature Rev Drug Discov 2018; 18: 273-294